## CI: The Cigna Group - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.2% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($259.74)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 1)

**1. ATTENTION CI SHAREHOLDERS: Investors Who Lost Money on The Cigna Group are Urged to Contact Levi & Korsinsky About an Ongoing Investigation**
- Source: WJTV | 20251217T120752 | Bearish | Relevance: 100%
- Levi & Korsinsky has initiated an investigation into The Cigna Group (NYSE:CI) concerning potential violations of federal securities laws. This follows Cigna's Q3 2025 earnings report, which revealed a higher Healthcare Medical Care Ratio (MCR) of 84.8% compared to 82.8% in Q3 2024, leading to a significant drop in the company's stock price by 17% on October 30, 2025. Investors who suffered losses are encouraged to contact Levi & Korsinsky for more information regarding the ongoing investigation.

**2. Does Cigna Group’s Recent Gains Reflect Its Long Term Potential In 2025?**
- Source: Simply Wall Street | 20251217T010759 | Bullish | Relevance: 100%
- This article analyzes Cigna Group (NYSE: CI) to determine if its current stock price reflects its long-term potential, suggesting it might be undervalued. Using a Discounted Cash Flow (DCF) analysis, the intrinsic value is estimated at $1,062 per share, indicating a significant 74.0% discount. Additionally, its current Price-to-Earnings (PE) ratio of 12.0x is well below industry averages, further supporting the undervaluation thesis based on its Fair Ratio framework.

**3. Does Cigna Group’s Recent Gains Reflect Its Long Term Potential In 2025?**
- Source: Simply Wall Street | 20251217T012346 | Bullish | Relevance: 100%
- Cigna Group (NYSE:CI) is currently trading at what appears to be a significant discount, with a valuation score of 5/6 and a potential 74.0% undervaluation based on discounted cash flow analysis. The stock also trades at a lower Price/Earnings ratio (12.0x) compared to the broader healthcare industry (23.9x) and its peer group (31.2x), suggesting it is undervalued given its earnings growth outlook. Investors can explore "Narratives" on Simply Wall St to understand different assumptions influencing Cigna's fair value.

**4. Has the CVS Stock Surge in 2025 Already Priced In Its Cash Flow Potential?**
- Source: Simply Wall Street | 20251217T153644 | Neutral | Relevance: 64%
- CVS Health (CVS) has seen a significant stock surge of 77.0% year-to-date, prompting a re-evaluation of its potential. Despite this rapid increase, Discounted Cash Flow (DCF) analysis and Price-to-Sales (P/S) ratios suggest the stock remains undervalued by 65.2% and materially undervalued, respectively. The article explores how differing investor narratives, influenced by factors like Medicare Advantage recovery or regulatory risks, can lead to varied intrinsic valuations for CVS.

**5. Understanding generational differences in dental budgeting**
- Source: Humana | 20251217T164153 | Neutral | Relevance: 62%
- New Humana research highlights significant generational differences in dental care budgeting, with Gen Z patients being more proactive in planning for expenses than older generations. Despite this, a notable portion of younger patients don't save for unplanned costs, while older generations like the Silent Generation often rely on Medicare and don't budget for dental needs. These findings underscore the need for tailored communication and flexible dental plan designs to address each generation's financial realities and encourage proactive oral health management.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 2 ($1.01M) |
| Sells | 2 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.1%)
- Blackrock Inc.: 8.3% (-1.1%)
- JPMORGAN CHASE & CO: 5.0% (+106.4%)
- State Street Corpora: 4.5% (-1.2%)
- Price (T.Rowe) Assoc: 4.2% (+9.8%)

### Key Risks

1. Long-term trend broken: trading 9.9% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.55 indicates undervaluation relative to growth. Forward P/E 8.9x stretched relative to 3% growth. Balance sheet: $3.1B free cash flow. Insider buying signal ($1.0M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $72.6B |
| Beta | 0.26 |
| 52W Range | $239.51 - $350.00 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.55 |
| Forward P/E | 8.9 |
| Current P/E | 9.2 |
| YoY Growth | 3.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 4.9% to 0.2% (-4.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.8pp (needs >3.0% for momentum thesis). MRS_5 (-2.1%) diverging from MRS_10 - short-term weakness emerging. Below SMA200 (0.90x), long-term trend not supportive. MACD histogram positive (0.99), confirming momentum. RSI neutral at 48. OFD pattern: -SUH (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.20% (CS: 58) | Neutral |
| RSI_14 | 48.5 | Neutral |
| MACD Histogram | 0.99 | Bullish |
| vs SMA20 | 0.999x | Below |
| vs SMA50 | 0.979x | Below |
| vs SMA200 | 0.901x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $271.90
- **Stop Loss:** $259.74 (4.5% risk)
- **Target:** $284.06 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 98
- **Position Value:** $26,646.20
- **Portfolio %:** 26.65%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-05 (Est: $7.90)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $7.64 | $7.83 | +2.5% |
| 2025Q2 | $7.15 | $7.20 | +0.6% |
| 2025Q1 | $6.35 | $6.74 | +6.2% |
| 2024Q4 | $7.82 | $6.64 | -15.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*